Xin Yi

Xin Yi, PhD

Assistant Professor of Clinical Pathology and Genomic Medicine, Academic Institute
Houston Methodist
Weill Cornell Medical College


Clinical Chemistry Fellowship


Biography

Dr. Xin Yi is a board-certified clinical chemist (DABCC) with broad expertise in clinical chemistry, endocrinology testing, therapeutic drug monitoring, toxicology, and clinical pharmacogenetics. She is a fellow of the AACC’s National Academy of Clinical Biochemistry (NACB), and the Co-director of the ComACC postdoctoral fellowship program at Houston Methodist Hospital. Her clinical services include supervising the professional activities in the sections of general and special chemistry, point of care, and diagnostic immunology. Prior to her current position, she completed her postdoctoral fellowship training in clinical chemistry at the University of Chicago after completing her PhD in clinical-bioanalytical chemistry at Cleveland State University.

Description of Research

Dr. Yi is interested in the application of new technologies, especially mass spectrometry and genetic analysis, in broader clinical diagnostic use. Her past research activities focused on developing novel diagnostic assays for hormone measurements using mass spectrometry, such as high-sensitive estradiol measurement to assist clinical management in pediatrics, men and postmenopausal women. Her studies in pharmacogenetics involved understanding the impact of genetic variations on therapeutic responses, such as responses to anticoagulant and antiplatelet agents, Warfarin and Clopidogrel. Her current research activities are focused on studying the expression of onco-proteins in tumor tissues using mass spectrometry, and utilizing this approach to aid cancer differential diagnoses and personalized cancer therapies.

Publications

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
Gontu, A, Srinivasan, S, Salazar, E, Nair, MS, Nissly, RH, Greenawalt, D, Bird, IM, Herzog, CM, Ferrari, MJ, Poojary, I, Katani, R, Lindner, SE, Minns, AM, Rossi, R, Christensen, PA, Castillo, B, Chen, J, Eagar, TN, Yi, X, Zhao, P, Leveque, C, Olsen, RJ, Bernard, DW, Gollihar, J, Kuchipudi, SV, Musser, JM & Kapur, V 2021, , Communications Biology, vol. 4, no. 1, 267. https://doi.org/10.1038/s42003-021-01813-y

Is Adding IgM Antibody to Polymerase Chain Reaction Testing Useful for COVID-19 Travel Screening?
Yi, X, Chan, CW & Yeo, KTJ 2021, , American Journal of Clinical Pathology, vol. 155, no. 3, pp. 321-323. https://doi.org/10.1093/ajcp/aqaa270

Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
Salazar, E, Kuchipudi, SV, Christensen, PA, Eagar, T, Yi, X, Zhao, P, Jin, Z, Long, SW, Olsen, RJ, Chen, J, Castillo, B, Leveque, C, Towers, D, Lavinder, J, Gollihar, J, Cardona, J, Ippolito, G, Nissly, R, Bird, I, Greenawalt, D, Rossi, RM, Gontu, A, Srinivasan, S, Poojary, I, Cattadori, IM, Hudson, PJ, Josleyn, NM, Prugar, L, Huie, K, Herbert, A, Bernard, DW, Dye, JM, Kapur, V & Musser, JM 2020, , Journal of Clinical Investigation, vol. 130, no. 12, pp. 6728-6738. https://doi.org/10.1172/JCI141206

Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG
Salazar, E, Christensen, PA, Graviss, EA, Nguyen, DT, Castillo, B, Chen, J, Lopez, BV, Eagar, TN, Yi, X, Zhao, P, Rogers, J, Shehabeldin, A, Joseph, D, Masud, F, Leveque, C, Olsen, RJ, Bernard, DW, Gollihar, J & Musser, JM 2021, , American Journal of Pathology, vol. 191, no. 1, pp. 90-107. https://doi.org/10.1016/j.ajpath.2020.10.008, https://doi.org/10.1016/j.ajpath.2020.10.008

Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Salazar, E, Christensen, PA, Graviss, EA, Nguyen, DT, Castillo, B, Chen, J, Lopez, BV, Eagar, TN, Yi, X, Zhao, P, Rogers, J, Shehabeldin, A, Joseph, D, Leveque, C, Olsen, RJ, Bernard, DW, Gollihar, J & Musser, JM 2020, , American Journal of Pathology, vol. 190, no. 11, pp. 2290-2303. https://doi.org/10.1016/j.ajpath.2020.08.001

Pathology Trainee Redeployment and Education During the COVID-19 Pandemic: An Institutional Experience
Monroig-Bosque, PDC, Hsu, JW, Lin, MS, Shehabeldin, AN, Rogers, JT, Kim, CF, Kalsekar, AG, Jin, Z, Cara, LR, Barbieri, AN, El-Zaatari, Z, Eskandari, G, Sheu, TG, Tomsula, JA, Long, SW, Zieske, AW, Leveque, CM, Salazar, E, Mody, DR, Schwartz, MR, Cykowski, MD, Yi, X, Powell, SZ & Thomas, JS 2020, , Academic Pathology, vol. 7. https://doi.org/10.1177/2374289520953548

Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization
Salazar, E, Kuchipudi, SV, Christensen, PA, Eagar, T, Yi, X, Zhao, P, Jin, Z, Long, SW, Olsen, RJ, Chen, J, Castillo, B, Leveque, C, Towers, D, Lavinder, JJ, Gollihar, J, Cardona, JA, Ippolito, GC, Nissly, RH, Bird, I, Greenawalt, D, Rossi, RM, Gontu, A, Srinivasan, S, Poojary, I, Cattadori, IM, Hudson, P, Josleyn, NM, Prugar, L, Huie, KE, Herbert, AS, Bernard, DW, Dye, JM, Kapur, V & Musser, JM 2020, , The Journal of clinical investigation, vol. 130, no. 12, pp. 6728-6738. https://doi.org/10.1172/JCI141206

What to Expect from Antibody Assays of SARS-CoV-2?
Yi, X & Cao, J 2020, , The journal of applied laboratory medicine, vol. 5, no. 5, pp. 1126-1130. https://doi.org/10.1093/jalm/jfaa100

Development of a Nonradioactive Platelet Serotonin Uptake and Release Assay by Micro-Liquid Chromatography Tandem Mass Spectrometry Using Minimal Blood Volume
Chan, SL, Yi, X, Wysocki, E, Bridgman, R, Gutierrez, J, Mikrut, K, Leung, EKY, Yeo, KTJ & Miller, JL 2019, , American Journal of Clinical Pathology, vol. 152, no. 6, pp. 718-724. https://doi.org/10.1093/ajcp/aqz094

Isotyping of Paraprotein Irresolvable by Routine Immunofixation Electrophoresis
Liu, H, Wilburn, C & Yi, X 2019, , The journal of applied laboratory medicine, vol. 4, no. 1, pp. 120-124. https://doi.org/10.1373/jalm.2018.026401

An HbA1c of 25%-Is It Real?
Moyer, AB, Yi, X & Miller, TN 2018, , The journal of applied laboratory medicine, vol. 3, no. 3, pp. 511-514. https://doi.org/10.1373/jalm.2018.026039

Reengineering Critical Laboratory Testing for Timely Chemotherapeutic Management
Yi, X, Leung, EKY, Mika, D, Wolsky, RJ, Van Slambrouck, C, Leanse, J, Nabhan, C & Yeo, KTJ 2018, , The journal of applied laboratory medicine, vol. 3, no. 2, pp. 240-249. https://doi.org/10.1373/jalm.2017.025973

Quality control practices for chemistry and immunochemistry in a cohort of 21 large academic medical centers
Rosenbaum, MW, Flood, JG, Melanson, SEF, Baumann, NA, Marzinke, MA, Rai, AJ, Hayden, J, Wu, AHB, Ladror, M, Lifshitz, MS, Scott, MG, Peck-Palmer, OM, Bowen, R, Babic, N, Sobhani, K, Giacherio, D, Bocsi, GT, Herman, DS, Wang, P, Toffaletti, J, Handel, E, Kelly, KA, Albeiroti, S, Wang, S, Zimmer, M, Driver, B, Yi, X, Wilburn, C & Lewandrowski, KB 2018, , American Journal of Clinical Pathology, vol. 150, no. 2, pp. 96-104. https://doi.org/10.1093/ajcp/aqy033

Diiodothyropropionic acid (DITPA) cross-reacts with thyroid function assays on different immunoassay platforms
Leung, EKY, Yi, X, Refetoff, S & Yeo, KTJ 2016, , Clinica Chimica Acta, vol. 453, pp. 203-204. https://doi.org/10.1016/j.cca.2015.12.008

Clinical evaluation of the QMS® Tacrolimus Immunoassay
Leung, EKY, Yi, X, Gloria, C & Yeo, KTJ 2014, , Clinica Chimica Acta, vol. 431, pp. 270-275. https://doi.org/10.1016/j.cca.2014.01.027

RNase L contributes to experimentally induced type 1 diabetes onset in mice
Zeng, C, Yi, X, Zipris, D, Liu, H, Zhang, L, Zheng, Q, Malathi, K, Jin, G & Zhou, A 2014, , Journal of Endocrinology, vol. 223, no. 3, pp. 277-287. https://doi.org/10.1530/JOE-14-0509

Lack of RNase L attenuates macrophage functions
Yi, X, Zeng, C, Liu, H, Chen, X, Zhang, P, Yun, BS, Jin, G & Zhou, A 2013, , PLoS ONE, vol. 8, no. 12, e81269. https://doi.org/10.1371/journal.pone.0081269

Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors
Zhong, B, Chennamaneni, S, Lama, R, Yi, X, Geldenhuys, WJ, Pink, JJ, Dowlati, A, Xu, Y, Zhou, A & Su, B 2013, , Journal of Medicinal Chemistry, vol. 56, no. 13, pp. 5306-5320. https://doi.org/10.1021/jm4004736

Identification of a class of novel tubulin inhibitors
Yi, X, Zhong, B, Smith, KM, Geldenhuys, WJ, Feng, Y, Pink, JJ, Dowlati, A, Xu, Y, Zhou, A & Su, B 2012, , Journal of Medicinal Chemistry, vol. 55, no. 7, pp. 3425-3435. https://doi.org/10.1021/jm300100d

From COX-2 inhibitor nimesulide to potent anti-cancer agent: Synthesis, in vitro, in vivo and pharmacokinetic evaluation
Zhong, B, Cai, X, Chennamaneni, S, Yi, X, Liu, L, Pink, JJ, Dowlati, A, Xu, Y, Zhou, A & Su, B 2012, , European Journal of Medicinal Chemistry, vol. 47, no. 1, pp. 432-444. https://doi.org/10.1016/j.ejmech.2011.11.012